Wow Doc580. I've made some what I viewed as realistic assessments about our trial results and our low chances to get a CD12 EUA based on how I view the FDA as such a conservative organization and not so optimal trial design. Got called out as a soft basher even though I've never shorted, flipped or sold a single share. But I am still optimistic in this 140 patient (CD16?) trial that can hopefully still get us to an eventual EUA/approval even though there are still some challenges with funding and trying to enroll patients as the pandemic numbers go down. But your post has really deflated my hopes since I know how much you love this drug. Please say it ain't so!